Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for ALK+ cancer patients: expanded access to experimental drug neladalkib

NCT ID NCT06834074

AVAILABLE Disease control Sponsor: Nuvalent Inc. Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 24 times

Summary

This program offers the experimental drug neladalkib to adults with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. The goal is to provide access to a promising therapy that targets the ALK mutation driving their cancer. Participants must have already tried at least one ALK-targeting medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AUSL della Romagna - Ravenna

    AVAILABLE

    Ravenna, 48121, Italy

  • Antoni van Leeuwenhoek Hospital

    AVAILABLE

    Amsterdam, 1006 BE, Netherlands

  • Azienda Ospedaliero Universitaria delle Marche

    AVAILABLE

    Ancona, 60126, Italy

  • BC Cancer - Vancouver

    AVAILABLE

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CHU de Nantes

    AVAILABLE

    Nantes, Pays de la Loire Region, 44800, France

  • Centre Leon Berard

    AVAILABLE

    Lyon, Auvergne-Rhône-Alpes, 69008, France

  • Cross Cancer Institute

    AVAILABLE

    Edmonton, Alberta, AB T6G 1Z2, Canada

  • Dana-Farber Cancer Institute

    AVAILABLE

    Boston, Massachusetts, 02215, United States

  • Duke University

    AVAILABLE

    Durham, North Carolina, 27708, United States

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    AVAILABLE

    Milan, 20133, Italy

  • GCS IUCT Oncopole

    AVAILABLE

    Toulouse, Occitanie, 31059, France

  • Gerencia de Gestión Integrada A Coruna

    AVAILABLE

    A Coruña, 15006, Spain

  • Henry Ford Cancer Institute

    AVAILABLE

    Detroit, Michigan, 48202, United States

  • Hospital Universitario 12 de Octubre

    AVAILABLE

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    AVAILABLE

    Barcelona, 08035, Spain

  • IRCCS Istituto Nazionale Tumori Regina Elena

    AVAILABLE

    Rome, 53, Italy

  • IRCCS Istituto Oncologico Veneto

    AVAILABLE

    Padova, 35128, Italy

  • Institut Gustave Roussy

    AVAILABLE

    Villejuif, Île-de-France Region, 94800, France

  • Kantonsspital Luzern

    AVAILABLE

    Lucerne, 6000, Switzerland

  • L'Istituto Europeo di Oncologia S.r.l.

    AVAILABLE

    Milan, 20141, Italy

  • Massachusetts General Hospital

    AVAILABLE

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    AVAILABLE

    New York, New York, 10065, United States

  • NYU Langone Health

    AVAILABLE

    New York, New York, 10016, United States

  • National Cancer Centre Singapore

    AVAILABLE

    Singapore, 168583, Singapore

  • National Cheng-Kung University Hospital

    AVAILABLE

    Tainan, 704, Taiwan

  • National Taiwan University Hospital

    AVAILABLE

    Taipei, 100, Taiwan

  • National University Hospital Singapore

    AVAILABLE

    Singapore, 119074, Singapore

  • Ospedale Italiano di Lugano

    AVAILABLE

    Viganello, 6962, Switzerland

  • Peter MacCallum Cancer Centre

    AVAILABLE

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Hospital

    AVAILABLE

    Toronto, Ontario, ON M5G 2M9, Canada

  • Royal North Shore Hospital

    AVAILABLE

    St Leonards, New South Wales, 2065, Australia

  • Seoul National University Hospital

    AVAILABLE

    Seoul, Jongno-gu, 03080, South Korea

  • Stichting Het Nederlands Kanker Instituut

    AVAILABLE

    Amsterdam, North Holland, 1066 CX, Netherlands

  • The Christie Hospital

    AVAILABLE

    Manchester, M20 4BX, United Kingdom

  • The Ohio State University

    AVAILABLE

    Columbus, Ohio, 43210, United States

  • The Royal Marsden Hospital

    AVAILABLE

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Royal Marsden Hospital

    AVAILABLE

    London, UK, SW3 6JJ, United Kingdom

  • The University of Texas MD Anderson Cancer Center

    AVAILABLE

    Houston, Texas, 77030, United States

  • University Medical Center Groningen

    AVAILABLE

    Groningen, 9713 GZ, Netherlands

  • University Of California Irvine Medical Center

    AVAILABLE

    Orange, California, 92868, United States

  • University of Chicago Medical Center

    AVAILABLE

    Chicago, Illinois, 60637, United States

  • University of Colorado Anschutz School of Medicine

    AVAILABLE

    Aurora, Colorado, 80045, United States

  • University of Washington / Fred Hutchinson Cancer Center

    AVAILABLE

    Seattle, Washington, 98109, United States

  • Uomi Cancer Center-Clinica Tres Torres

    AVAILABLE

    Barcelona, 08017, Spain

  • Washington University in St. Louis

    AVAILABLE

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER